Santhosh Francis Neelamkavil

USPTO Granted Patents = 23 (Patent Applications = 15)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 21 (Patent Applications = 10)

Average Co-Inventor Count = 8.5

ph-index = 3

Forward Citations = 30(Granted Patents)

Location History:

Scotch Plains, NJ (US) (2015)
Edison, NJ (US) (2014 - 2024)

Company Filing History:

20 out of 2,405

Merck Sharp + Dohme Corp.

patents

2 out of 32

Protagonist Therapeutics, Inc.

Janssen Pharmaceutica Nv

Mochida Pharmaceutical Co., Ltd.

patents

7. 1 out of 410

Janssen Biotech, Inc.

patents

where one patent can have more than one assignee

Years Active: 2014-2025

where 'Filed Patents' based on already Granted Patents

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12478617 - Lipidated peptide inhibitors of interleukin-23 receptor (2025-11-25),

2. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2025-06-03),

3. 12281114 - NK3 modulators and uses thereof (2025-04-21),

4. 12030872 - N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2024-07-09),

5. 11939361 - Compositions of peptide inhibitors of Interleukin-23 receptor (2024-03-26),

6. 11174248 - Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-16),

7. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-02),

8. 10239863 - Factor XIa inhibitors (2019-03-26),

9. 10214512 - Factor XIA inhibitors (2019-02-26),

10. 10123995 - Factor XIa inhibitors (2018-11-13),

11. 10093683 - Factor XIa inhibitors (2018-10-09),

12. 10081617 - Factor XIa inhibitors (2018-09-25),

13. 9944643 - Factor XIa inhibitors (2018-04-17),

14. 9809545 - Factor XIa inhibitors (2017-11-07),

15. 9676723 - Factor XIa inhibitors (2017-06-13),

Title: Innovations and Contributions of Santhosh Francis Neelamkavil

Introduction: Santhosh Francis Neelamkavil, based in Edison, NJ, is a prominent inventor known for his significant contributions to the pharmaceutical field. With an impressive portfolio of 20 patents, he has made substantial advancements, particularly in developing therapies for neurodegenerative and autoimmune diseases.

Latest Patents: Among his latest innovations, Santhosh's patents include N-heteroaryl indazole derivatives as LRRK2 inhibitors. This invention focuses on substituted N-heteroaryl indazole derivatives that act as potent inhibitors of the LRRK2 kinase, potentially aiding in the treatment and prevention of diseases like Parkinson's Disease. Additionally, he has developed compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R). These compositions aim to address autoimmune inflammation and related diseases, showcasing his commitment to advancing medical therapeutics.

Career Highlights: Santhosh has built an impressive career, having worked with leading pharmaceutical companies such as Merck Sharp & Dohme Corporation and Merck Canada Inc. His background with these esteemed organizations has reinforced his expertise in drug development and innovation, paving the way for significant breakthroughs in medicine.

Collaborations: Throughout his career, Santhosh has collaborated with esteemed colleagues in the field, including Scott D. Edmondson and Weiguo Liu. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the development of innovative solutions in pharmaceutical research.

Conclusion: Santhosh Francis Neelamkavil exemplifies the spirit of innovation in the pharmaceutical industry. With a robust portfolio of patents and a commitment to improving health outcomes, his work stands as a testament to the power of research and collaboration in addressing some of the most pressing health challenges of our time.

This text is generated by artificial intelligence and may not be accurate.